Skip to main content
Log in

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Patients with stage 2 hypertension require large absolute reductions in blood pressure (BP) to achieve recommended BP goals. Combination therapy with the direct renin inhibitor, aliskiren, and the angiotensin receptor blocker, valsartan, has been shown to produce greater BP reductions than either agent alone in a double-blind study in 1797 hypertensive patients.

Methods

This post-hoc analysis evaluated the BP-lowering efficacy of aliskiren in combination with valsartan in a subset of patients (n=581) with stage 2 hypertension (baseline mean sitting systolic BP [msSBP] ≥160 mmHg). Patients were randomized to receive aliskiren/valsartan 150/160 mg, aliskiren 150 mg, valsartan 160 mg, or placebo once daily for 4 weeks followed by 4 weeks at double the initial dose. Mean changes from baseline in msSBP and mean sitting diastolic BP were assessed at week-8 endpoint (intent-to-treat population).

Results

Aliskiren/valsartan 300/320 mg reduced BP from baseline by 22.5/11.4 mmHg at week-8 endpoint. BP reductions with combination therapy were significantly greater than with aliskiren 300 mg (17.3/8.9 mmHg, P<0.05), valsartan 320 mg (15.5/8.3 mmHg, P<0.01), or with placebo (7.9/3.7 mmHg, P<0.0001). BP control rates (<140/90 mmHg) were also significantly higher (P<0.05) with aliskiren/valsartan 300/320 mg (29.8%) compared with either aliskiren 300 mg (19.0%) or valsartan 320 mg (13.8%) monotherapy, or placebo (8.9%). All treatments were generally well tolerated.

Conclusion

Combination therapy with aliskiren and valsartan provided significantly greater BP reductions over aliskiren or valsartan monotherapy and is an appropriate option for management of BP in patients with stage 2 hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146.

    Article  PubMed  Google Scholar 

  2. National Center for Health Statistics. The National Health and Nutrition Examination Survey (NHANES) 2005-06 data files. Available at: www.cdc.gov/nchs/about/major/nhanes/datalink.htm. Accessed September 19, 2008.

  3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.

    Article  PubMed  Google Scholar 

  4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.

    Article  PubMed  CAS  Google Scholar 

  5. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.

    Article  PubMed  CAS  Google Scholar 

  6. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17:495–501.

    Article  PubMed  CAS  Google Scholar 

  7. Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7:361–372.

    Article  PubMed  CAS  Google Scholar 

  8. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279–289.

    Article  PubMed  CAS  Google Scholar 

  9. Everett BM, Glynn RJ, Danielson E, Ridker PM. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther. 2008;30:661–672.

    Article  PubMed  CAS  Google Scholar 

  10. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16:592–599.

    Article  PubMed  CAS  Google Scholar 

  11. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007;67:1767–1792.

    Article  PubMed  CAS  Google Scholar 

  12. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446.

    Article  PubMed  CAS  Google Scholar 

  13. McMurray J, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17–24.

    Article  CAS  PubMed  Google Scholar 

  14. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–229.

    Article  PubMed  CAS  Google Scholar 

  15. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–161.

    PubMed  CAS  Google Scholar 

  16. NCEP. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.

    Google Scholar 

  17. Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens. 2007;21:780–787.

    Article  PubMed  CAS  Google Scholar 

  18. Calhoun D, Villamil A, Chrysant SG, Schober B, Fang H, Zhang J. Antihypertensive efficacy of aliskiren/hydrochlorothiazide (HCT) combinations in patients with stage 2 hypertension: subgroup analysis of a randomized, double-blind, factorial trial. Hypertension. 2008;52:e97. Abstract P209.

    Google Scholar 

  19. Uresin Y, Taylor A, Kilo C, Fang H, Lukashevich L, Keefe DL. Aliskiren monotherapy lowers blood pressure more effectively than ramipril monotherapy in patients with diabetes and grade 2 hypertension: subgroup analysis of an 8-week, double-blind trial. J Hypertens. 2008;26:S479. Abstract PS433/THU/462.

    Google Scholar 

  20. Weir MR, Bush C, Anderson DR, Zhang J, Keefe DL, Satlin A. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007;1:264–277.

    Article  Google Scholar 

  21. Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens. 2006;20:169–175.

    Article  PubMed  CAS  Google Scholar 

  22. Jamerson KA, Basile J. Prompt, aggressive BP lowering in high-risk patients. J Clin Hypertens (Greenwich). 2008;10:40–48.

    Article  Google Scholar 

  23. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031.

    Article  PubMed  CAS  Google Scholar 

  24. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2049–2051.

    Article  PubMed  CAS  Google Scholar 

  25. Weycker D, Edelsberg J, Vincze G, Levy DG, Kartashov A, Oster G. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother. 2008;42:169–176.

    Article  PubMed  Google Scholar 

  26. Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin Nephrol. 2005;64:180–189.

    PubMed  CAS  Google Scholar 

  27. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Am J Nephrol. 2004;24:543–548.

    Article  PubMed  CAS  Google Scholar 

  28. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.

    Article  PubMed  CAS  Google Scholar 

  29. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109:307–314.

    Article  PubMed  CAS  Google Scholar 

  30. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system. N Engl J Med. 2004;351:585–592.

    Article  PubMed  CAS  Google Scholar 

  31. Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin. 2008;24:1039–1047.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Steven A. Yarows.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yarows, S.A., Oparil, S., Patel, S. et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Therapy 25, 1288–1302 (2008). https://doi.org/10.1007/s12325-008-0123-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0123-x

Keywords

Navigation